Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

kollektiivautor
ODYSSEY Outcomes Committees and Investigators
vastutusandmed
Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, and on behalf of ODYSSEY Outcomes Committees and Investigators, [Margus Viigimaa et al.]
kirjastus/väljaandja
American College of Cardiology
ajakirja aastakäik number kuu
Vol. 78, 5
ilmumisaasta
leheküljed
p. 421–433 : ill
võtmesõna
lipoprotein(a)
low-density lipoprotein cholesterol
PCSK9 inhibitor
ISSN
0735-1097
TTÜ struktuuriüksus
keel
inglise
Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., ODYSSEY Outcomes Committees and Investigators, Viigimaa, M. et al. Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol // Journal of the American College of Cardiology (2021) Vol. 78, 5, p. 421–433 : ill. https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102